{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T17:58:16Z","timestamp":1767981496250,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2011,4,29]],"date-time":"2011-04-29T00:00:00Z","timestamp":1304035200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,4,29]],"date-time":"2011-04-29T00:00:00Z","timestamp":1304035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1038\/leu.2011.87","type":"journal-article","created":{"date-parts":[[2011,4,29]],"date-time":"2011-04-29T08:39:20Z","timestamp":1304066360000},"page":"1111-1121","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Acute lymphoblastic leukemia cells treated with CpG oligodeoxynucleotides, IL-4 and CD40 ligand facilitate enhanced anti-leukemic CTL responses"],"prefix":"10.1038","volume":"25","author":[{"given":"D","family":"Fabricius","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Breckerbohm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Vollmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Queudeville","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S M","family":"Eckhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Fulda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K-M","family":"Debatin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Jahrsd\u00f6rfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L H","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,4,29]]},"reference":[{"key":"BFleu201187_CR1","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(01)05581-7","volume":"358","author":"RG Feltbower","year":"2001","unstructured":"Feltbower RG, Moorman AV, Dovey G, Kinsey SE, McKinney PA . Incidence of childhood acute lymphoblastic leukaemia in Yorkshire, UK. Lancet 2001; 358: 385\u2013387.","journal-title":"Lancet"},{"key":"BFleu201187_CR2","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(08)60457-2","volume":"371","author":"CH Pui","year":"2008","unstructured":"Pui CH, Robison LL, Look AT . Acute lymphoblastic leukaemia. Lancet 2008; 371: 1030\u20131043.","journal-title":"Lancet"},{"key":"BFleu201187_CR3","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1038\/sj.leu.2401973","volume":"14","author":"M Schrappe","year":"2000","unstructured":"Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze G et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 2000; 14: 2205\u20132222.","journal-title":"Leukemia"},{"key":"BFleu201187_CR4","first-page":"1","volume":"86","author":"C Uderzo","year":"2001","unstructured":"Uderzo C, Conter V, Dini G, Locatelli F, Miniero R, Tamaro P . Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies. Haematologica 2001; 86: 1\u20137.","journal-title":"Haematologica"},{"key":"BFleu201187_CR5","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1046\/j.1365-2141.2002.03291.x","volume":"116","author":"AJ Alessandri","year":"2002","unstructured":"Alessandri AJ, Reid GS, Bader SA, Massing BG, Sorensen PH, Schultz KR . ETV6 (TEL)-AML1 pre-B acute lymphoblastic leukaemia cells are associated with a distinct antigen-presenting phenotype. Br J Haematol 2002; 116: 266\u2013272.","journal-title":"Br J Haematol"},{"key":"BFleu201187_CR6","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood.V88.1.41.41","volume":"88","author":"AA Cardoso","year":"1996","unstructured":"Cardoso AA, Schultze JL, Boussiotis VA, Freeman GJ, Seamon MJ, Laszlo S et al. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood 1996; 88: 41\u201348.","journal-title":"Blood"},{"key":"BFleu201187_CR7","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/S0301-472X(99)00083-1","volume":"27","author":"P Yotnda","year":"1999","unstructured":"Yotnda P, Mintz P, Grigoriadou K, Lemonnier F, Vilmer E, Langlade-Demoyen P . Analysis of T-cell defects in the specific immune response against acute lymphoblastic leukemia cells. Exp Hematol 1999; 27: 1375\u20131383.","journal-title":"Exp Hematol"},{"key":"BFleu201187_CR8","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1182\/blood-2004-06-2468","volume":"105","author":"GS Reid","year":"2005","unstructured":"Reid GS, She K, Terrett L, Food MR, Trudeau JD, Schultz KR . CpG stimulation of precursor B-lineage acute lymphoblastic leukemia induces a distinct change in costimulatory molecule expression and shifts allogeneic T cells toward a Th1 response. Blood 2005; 105: 3641\u20133647.","journal-title":"Blood"},{"key":"BFleu201187_CR9","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/374546a0","volume":"374","author":"AM Krieg","year":"1995","unstructured":"Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374: 546\u2013549.","journal-title":"Nature"},{"key":"BFleu201187_CR10","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood.V95.3.999.003k10_999_1006","volume":"95","author":"T Decker","year":"2000","unstructured":"Decker T, Schneller F, Sparwasser T, Tretter T, Lipford GB, Wagner H et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood 2000; 95: 999\u20131006.","journal-title":"Blood"},{"key":"BFleu201187_CR11","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1158\/1078-0432.CCR-04-1890","volume":"11","author":"B Jahrsd\u00f6rfer","year":"2005","unstructured":"Jahrsd\u00f6rfer B, Muhlenhoff L, Blackwell SE, Wagner M, Poeck H, Hartmann E et al. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res 2005; 11: 1490\u20131499.","journal-title":"Clin Cancer Res"},{"key":"BFleu201187_CR12","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1038\/sj.leu.2404870","volume":"21","author":"B Jahrsd\u00f6rfer","year":"2007","unstructured":"Jahrsd\u00f6rfer B, Blackwell S, Weiner G . The effects of CpG ODN on CLL proliferation, apoptosis or phenotype could have an impact on its clinical utility. Leukemia 2007; 21: 2354\u20132355; author reply 2355\u20132356.","journal-title":"Leukemia"},{"key":"BFleu201187_CR13","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1182\/blood-2006-02-002055","volume":"109","author":"H Fujii","year":"2007","unstructured":"Fujii H, Trudeau JD, Teachey DT, Fish JD, Grupp SA, Schultz KR et al. In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides. Blood 2007; 109: 2008\u20132013.","journal-title":"Blood"},{"key":"BFleu201187_CR14","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1182\/blood-2009-02-203984","volume":"114","author":"AE Seif","year":"2009","unstructured":"Seif AE, Barrett DM, Milone M, Brown VI, Grupp SA, Reid GS . Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses. Blood 2009; 114: 2459\u20132466.","journal-title":"Blood"},{"key":"BFleu201187_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/0145-2126(90)90134-U","volume":"14","author":"CG Begley","year":"1990","unstructured":"Begley CG, Burton JD, Tsudo M, Brownstein BH, Ambrus Jr JL, Waldmann TA . Human B lymphocytes express the p75 component of the interleukin 2 receptor. Leuk Res 1990; 14: 263\u2013271.","journal-title":"Leuk Res"},{"key":"BFleu201187_CR16","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1038\/sj.leu.2400836","volume":"11","author":"E Paietta","year":"1997","unstructured":"Paietta E, Racevskis J, Neuberg D, Rowe JM, Goldstone AH, Wiernik PH . Expression of CD25 (interleukin-2 receptor alpha chain) in adult acute lymphoblastic leukemia predicts for the presence of BCR\/ABL fusion transcripts: results of a preliminary laboratory analysis of ECOG\/MRC Intergroup Study E2993. Eastern Cooperative Oncology Group\/Medical Research Council. Leukemia 1997; 11: 1887\u20131890.","journal-title":"Leukemia"},{"key":"BFleu201187_CR17","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/S0301-472X(00)00144-2","volume":"28","author":"T Decker","year":"2000","unstructured":"Decker T, Schneller F, Kronschnabl M, Dechow T, Lipford GB, Wagner H et al. Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype. Exp Hematol 2000; 28: 558\u2013568.","journal-title":"Exp Hematol"},{"key":"BFleu201187_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.0105-2896.2004.00203.x","volume":"202","author":"PE Kovanen","year":"2004","unstructured":"Kovanen PE, Leonard WJ . Cytokines and immunodeficiency diseases: critical roles of the gamma(c)-dependent cytokines interleukins 2, 4, 7, 9, 15, and 21, and their signaling pathways. Immunol Rev 2004; 202: 67\u201383.","journal-title":"Immunol Rev"},{"key":"BFleu201187_CR19","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1126\/science.1077002","volume":"298","author":"K Ozaki","year":"2002","unstructured":"Ozaki K, Spolski R, Feng CG, Qi CF, Cheng J, Sher A et al. A critical role for IL-21 in regulating immunoglobulin production. Science 2002; 298: 1630\u20131634.","journal-title":"Science"},{"key":"BFleu201187_CR20","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1189\/jlb.69.1.81","volume":"69","author":"B Jahrsd\u00f6rfer","year":"2001","unstructured":"Jahrsd\u00f6rfer B, Hartmann G, Racila E, Jackson W, Muhlenhoff L, Meinhardt G et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 2001; 69: 81\u201388.","journal-title":"J Leukoc Biol"},{"key":"BFleu201187_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev.immunol.22.012703.104533","volume":"22","author":"SA Quezada","year":"2004","unstructured":"Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ . CD40\/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol 2004; 22: 307\u2013328.","journal-title":"Annu Rev Immunol"},{"key":"BFleu201187_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1089\/oli.2005.15.51","volume":"15","author":"B Jahrsd\u00f6rfer","year":"2005","unstructured":"Jahrsd\u00f6rfer B, Blackwell SE, Wooldridge JE, Taylor CM, Weiner GJ . Serum alters the uptake and biologic activity of CpG oligodeoxynucleotides in B cell chronic lymphocytic leukemia. Oligonucleotides 2005; 15: 51\u201359.","journal-title":"Oligonucleotides"},{"key":"BFleu201187_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.uct.2007.11.003","volume":"3","author":"B Jahrsd\u00f6rfer","year":"2008","unstructured":"Jahrsd\u00f6rfer B, Weiner GJ . CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther 2008; 3: 27\u201332.","journal-title":"Update Cancer Ther"},{"key":"BFleu201187_CR24","first-page":"3310","volume":"95","author":"M Schrappe","year":"2000","unstructured":"Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000; 95: 3310\u20133322.","journal-title":"Blood"},{"key":"BFleu201187_CR25","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1182\/blood.V100.2.654","volume":"100","author":"BA Nijmeijer","year":"2002","unstructured":"Nijmeijer BA, Willemze R, Falkenburg JH . An animal model for human cellular immunotherapy: specific eradication of human acute lymphoblastic leukemia by cytotoxic T lymphocytes in NOD\/scid mice. Blood 2002; 100: 654\u2013660.","journal-title":"Blood"},{"key":"BFleu201187_CR26","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1182\/blood-2003-12-4146","volume":"104","author":"T Luft","year":"2004","unstructured":"Luft T, Maraskovsky E, Schnurr M, Knebel K, Kirsch M, Gorner M et al. Tuning the volume of the immune response: strength and persistence of stimulation determine migration and cytokine secretion of dendritic cells. Blood 2004; 104: 1066\u20131074.","journal-title":"Blood"},{"key":"BFleu201187_CR27","doi-asserted-by":"publisher","first-page":"5920","DOI":"10.4049\/jimmunol.177.9.5920","volume":"177","author":"D Fabricius","year":"2006","unstructured":"Fabricius D, O\u2019Dorisio M, Blackwell S, Jahrsdorfer B . Human plasmacytoid dendritic cell function: inhibition of IFN-alpha secretion and modulation of immune phenotype by vasoactive intestinal peptide. J Immunol 2006; 177: 5920\u20135927.","journal-title":"J Immunol"},{"key":"BFleu201187_CR28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1189\/jlb.72.1.83","volume":"72","author":"B Jahrsd\u00f6rfer","year":"2002","unstructured":"Jahrsd\u00f6rfer B, Jox R, Muhlenhoff L, Tschoep K, Krug A, Rothenfusser S et al. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN. J Leukoc Biol 2002; 72: 83\u201392.","journal-title":"J Leukoc Biol"},{"key":"BFleu201187_CR29","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1189\/jlb.0604373","volume":"77","author":"B Jahrsd\u00f6rfer","year":"2005","unstructured":"Jahrsd\u00f6rfer B, Wooldridge JE, Blackwell SE, Taylor CM, Griffith TS, Link BK et al. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol 2005; 77: 378\u2013387.","journal-title":"J Leukoc Biol"},{"key":"BFleu201187_CR30","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1182\/blood-2006-03-014001","volume":"108","author":"B Jahrsd\u00f6rfer","year":"2006","unstructured":"Jahrsd\u00f6rfer B, Blackwell SE, Wooldridge JE, Huang J, Andreski MW, Jacobus LS et al. B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. Blood 2006; 108: 2712\u20132719.","journal-title":"Blood"},{"key":"BFleu201187_CR31","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1038\/sj.leu.2402672","volume":"16","author":"E Todisco","year":"2002","unstructured":"Todisco E, Gaipa G, Biagi E, Bonamino M, Gramigna R, Introna M et al. CD40 ligand-stimulated B cell precursor leukemic cells elicit interferon-gamma production by autologous bone marrow T cells in childhood acute lymphoblastic leukemia. Leukemia 2002; 16: 2046\u20132054.","journal-title":"Leukemia"},{"key":"BFleu201187_CR32","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1038\/sj.leu.2404390","volume":"20","author":"G D\u2019Amico","year":"2006","unstructured":"D\u2019Amico G, Bonamino M, Dander E, Marin V, Basso G, Balduzzi A et al. T cells stimulated by CD40L positive leukemic blasts-pulsed dendritic cells meet optimal functional requirements for adoptive T-cell therapy. Leukemia 2006; 20: 2015\u20132024.","journal-title":"Leukemia"},{"key":"BFleu201187_CR33","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.beha.2004.05.011","volume":"17","author":"G D\u2019Amico","year":"2004","unstructured":"D\u2019Amico G, Marin V, Biondi A, Bonamino MH . Potential use of CD40 ligand for immunotherapy of childhood B-cell precursor acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2004; 17: 465\u2013477.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFleu201187_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1196\/annals.1358.008","volume":"1062","author":"D Messmer","year":"2005","unstructured":"Messmer D, Kipps TJ . CD154 gene therapy for human B-cell malignancies. Ann N Y Acad Sci 2005; 1062: 51\u201360.","journal-title":"Ann N Y Acad Sci"},{"key":"BFleu201187_CR35","doi-asserted-by":"publisher","first-page":"4531","DOI":"10.4049\/jimmunol.168.9.4531","volume":"168","author":"V Hornung","year":"2002","unstructured":"Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T et al. Quantitative expression of toll-like receptor 1\u201310 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002; 168: 4531\u20134537.","journal-title":"J Immunol"},{"key":"BFleu201187_CR36","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ccr.2010.11.014","volume":"19","author":"LH Meyer","year":"2011","unstructured":"Meyer LH, Eckhoff SM, Queudeville M, Kraus JM, Giordan M, Stursberg J et al. Early relapse in ALL is identified by time to leukemia in NOD\/SCID mice and is characterized by a gene signature involving survival pathways. Cancer Cell 2011; 19: 206\u2013217.","journal-title":"Cancer Cell"},{"key":"BFleu201187_CR37","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/(SICI)1521-4141(199901)29:01<45::AID-IMMU45>3.0.CO;2-I","volume":"29","author":"MJ Deeths","year":"1999","unstructured":"Deeths MJ, Mescher MF . ICAM-1 and B7\u20131 provide similar but distinct costimulation for CD8+ T cells, while CD4+ T cells are poorly costimulated by ICAM-1. Eur J Immunol 1999; 29: 45\u201353.","journal-title":"Eur J Immunol"},{"key":"BFleu201187_CR38","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev.immunol.16.1.323","volume":"16","author":"E Pamer","year":"1998","unstructured":"Pamer E, Cresswell P . Mechanisms of MHC class I--restricted antigen processing. Annu Rev Immunol 1998; 16: 323\u2013358.","journal-title":"Annu Rev Immunol"},{"key":"BFleu201187_CR39","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/jlb.63.4.418","volume":"63","author":"MF Mackey","year":"1998","unstructured":"Mackey MF, Barth Jr RJ, Noelle RJ . The role of CD40\/CD154 interactions in the priming, differentiation, and effector function of helper and cytotoxic T cells. J Leukoc Biol 1998; 63: 418\u2013428.","journal-title":"J Leukoc Biol"},{"key":"BFleu201187_CR40","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00277-007-0256-z","volume":"86","author":"W Luczynski","year":"2007","unstructured":"Luczynski W, Kowalczuk O, Ilendo E, Stasiak-Barmuta A, Krawczuk-Rybak M . Upregulation of antigen-processing machinery components at mRNA level in acute lymphoblastic leukemia cells after CD40 stimulation. Ann Hematol 2007; 86: 339\u2013345.","journal-title":"Ann Hematol"},{"key":"BFleu201187_CR41","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1080\/08880010050211349","volume":"17","author":"A Borgmann","year":"2000","unstructured":"Borgmann A, Baldy C, von Stackelberg A, Beyermann B, Fichtner I, Nurnberg P et al. Childhood all blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD\/SCID mice. Pediatr Hematol Oncol 2000; 17: 635\u2013650.","journal-title":"Pediatr Hematol Oncol"},{"key":"BFleu201187_CR42","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1038\/sj.leu.2401236","volume":"12","author":"WA Hudson","year":"1998","unstructured":"Hudson WA, Li Q, Le C, Kersey JH . Xenotransplantation of human lymphoid malignancies is optimized in mice with multiple immunologic defects. Leukemia 1998; 12: 2029\u20132033.","journal-title":"Leukemia"},{"key":"BFleu201187_CR43","first-page":"686","volume":"4","author":"B Jahrsd\u00f6rfer","year":"2003","unstructured":"Jahrsd\u00f6rfer B, Weiner GJ . CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy. Curr Opin Investig Drugs 2003; 4: 686\u2013690.","journal-title":"Curr Opin Investig Drugs"},{"key":"BFleu201187_CR44","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1084\/jem.176.5.1283","volume":"176","author":"LM Faber","year":"1992","unstructured":"Faber LM, van Luxemburg-Heijs SA, Willemze R, Falkenburg JH . Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med 1992; 176: 1283\u20131289.","journal-title":"J Exp Med"},{"key":"BFleu201187_CR45","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.beha.2004.05.008","volume":"17","author":"JH Falkenburg","year":"2004","unstructured":"Falkenburg JH, Willemze R . Minor histocompatibility antigens as targets of cellular immunotherapy in leukaemia. Best Pract Res Clin Haematol 2004; 17: 415\u2013425.","journal-title":"Best Pract Res Clin Haematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201187.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201187","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201187.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T12:06:58Z","timestamp":1712405218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,29]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2011,7]]}},"alternative-id":["BFleu201187"],"URL":"https:\/\/doi.org\/10.1038\/leu.2011.87","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,29]]},"assertion":[{"value":"1 November 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}